NDAOPHTHALMICSOLUTION/DROPS
Approved
May 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
7
Data completeness
5/8 — Partial
MIEBO (perfluorohexyloctane) by Bausch + Lomb is perfluorohexyloctane, a semifluorinated alkane, contains 6 perfluorinated carbon atoms and 8 hydrogenated carbon atoms. First approved in 2023.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIEBO is a semifluorinated alkane ophthalmic solution approved in May 2023 for dry eye disease (DED). It forms a monolayer at the air-liquid interface of the tear film to reduce tear evaporation, though its exact mechanism in DED remains incompletely understood. This represents a novel chemical class approach to a large, underserved patient population.
$9MPart D
Peak11.0 years to LOEEarly commercial phase with modest Medicare utilization; brand team expansion likely ongoing as market penetration grows and awareness increases among prescribers.
Mechanism of Action
Perfluorohexyloctane, a semifluorinated alkane, contains 6 perfluorinated carbon atoms and 8 hydrogenated carbon atoms. Perfluorohexyloctane forms a monolayer at the air-liquid interface of the tear film which can be expected to reduce evaporation. The exact mechanism of action for MIEBO in DED is…
Pharmacologic Class:
Semifluorinated Alkane
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease
Started Feb 2026
260 enrolled
Dry Eye Disease (DED)
A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
Started Dec 2025
0Dry Eye Disease
A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear
Started Jul 2025
104 enrolled
Dry Eye
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
Started Jul 2024
216 enrolled
Dry Eye
A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy
Started Apr 2024
97 enrolled
Dry Eye
Worked on MIEBO at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.